Immunologic Characterization and T cell Receptor Repertoires of Expanded Tumor-infiltrating Lymphocytes in Patients with Renal Cell Carcinoma.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
07 2023
07 2023
Historique:
received:
19
12
2022
revised:
27
03
2023
accepted:
21
06
2023
medline:
25
7
2023
pubmed:
24
7
2023
entrez:
24
7
2023
Statut:
epublish
Résumé
The successful use of expanded tumor-infiltrating lymphocytes (TIL) in adoptive TIL therapies has been reported, but the effects of the TIL expansion, immunophenotype, function, and T cell receptor (TCR) repertoire of the infused products relative to the tumor microenvironment (TME) are not well understood. In this study, we analyzed the tumor samples ( TILs are a heterogenous group of immune cells that recognize and attack the tumor, thus are utilized in various clinical trials. In our study, we explored the TILs in patients with kidney cancer by expanding the TILs using a clinical-grade protocol, as well as observed their characteristics and ability to recognize the tumor using in-depth experimental and computational tools.
Identifiants
pubmed: 37484198
doi: 10.1158/2767-9764.CRC-22-0514
pii: CRC-22-0514
pmc: PMC10361538
doi:
Substances chimiques
Receptors, Antigen, T-Cell
0
Receptors, Antigen, T-Cell, alpha-beta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1260-1276Informations de copyright
© 2023 The Authors; Published by the American Association for Cancer Research.
Références
Immunity. 2019 Jan 15;50(1):195-211.e10
pubmed: 30635237
Nucleic Acids Res. 2020 Jan 8;48(D1):D1057-D1062
pubmed: 31588507
Cancer Immunol Immunother. 2015 Oct;64(10):1241-50
pubmed: 26105626
Scand J Immunol. 2012 Feb;75(2):157-67
pubmed: 21955245
N Engl J Med. 2022 Dec 8;387(23):2113-2125
pubmed: 36477031
Oncoimmunology. 2021 Jan 21;10(1):1860482
pubmed: 33537169
Science. 2016 Apr 8;352(6282):189-96
pubmed: 27124452
Genome Biol. 2016 Nov 17;17(1):231
pubmed: 27855702
Cancer Cell. 2021 Nov 8;39(11):1497-1518.e11
pubmed: 34715028
J Exp Med. 2018 Oct 1;215(10):2520-2535
pubmed: 30154266
J Clin Oncol. 2021 Aug 20;39(24):2656-2666
pubmed: 33979178
Leukemia. 2021 May;35(5):1365-1379
pubmed: 33785863
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Oncotarget. 2017 Dec 6;8(69):113345-113359
pubmed: 29371915
Nat Commun. 2019 Sep 2;10(1):3931
pubmed: 31477722
Innovation (Camb). 2021 Jul 01;2(3):100141
pubmed: 34557778
Cell. 2018 Nov 1;175(4):998-1013.e20
pubmed: 30388456
Br J Cancer. 2015 Apr 28;112(9):1510-8
pubmed: 25867267
Cell Rep. 2017 Sep 19;20(12):2921-2934
pubmed: 28930685
Annu Rev Immunol. 2019 Apr 26;37:457-495
pubmed: 30676822
Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230
pubmed: 29845338
Blood. 2009 Nov 5;114(19):4099-107
pubmed: 19706884
Nat Immunol. 2019 Mar;20(3):326-336
pubmed: 30778252
Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):6086-6091
pubmed: 28533380
Sci Rep. 2022 Mar 30;12(1):5377
pubmed: 35354899
Immunity. 2019 Dec 17;51(6):1043-1058.e4
pubmed: 31810882
Nat Commun. 2022 Apr 11;13(1):1981
pubmed: 35411050
Nat Immunol. 2020 Oct;21(10):1256-1266
pubmed: 32839610
Nature. 2019 Jul;571(7764):265-269
pubmed: 31207605
Nat Methods. 2021 Aug;18(8):873-880
pubmed: 32632239
J Immunother. 2011 Mar;34(2):212-20
pubmed: 21304398
Nat Rev Urol. 2020 Mar;17(3):137-150
pubmed: 32020040
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
PLoS Comput Biol. 2015 Nov 25;11(11):e1004503
pubmed: 26606115
Nat Commun. 2020 May 7;11(1):2246
pubmed: 32382059
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214
pubmed: 33437048
Trends Immunol. 2020 Jan;41(1):17-28
pubmed: 31810790
Nat Biotechnol. 2020 Oct;38(10):1194-1202
pubmed: 32341563
Nature. 2021 Sep;597(7875):279-284
pubmed: 34471285
Cancer Cell. 2020 Sep 14;38(3):380-399.e13
pubmed: 32649887
Proc Natl Acad Sci U S A. 2022 Feb 15;119(7):
pubmed: 35140181
F1000Res. 2020 Jan 27;9:47
pubmed: 32789006
JCO Oncol Pract. 2022 Mar;18(3):187-196
pubmed: 34529499
Nat Biotechnol. 2018 Dec 03;:
pubmed: 30531897
Science. 2021 Dec 17;374(6574):abe6474
pubmed: 34914499
Nat Commun. 2022 Oct 11;13(1):5988
pubmed: 36220826
Commun Biol. 2021 Jan 27;4(1):122
pubmed: 33504936
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Nature. 2019 Dec;576(7787):465-470
pubmed: 31827286
Front Oncol. 2019 May 28;9:439
pubmed: 31192136
Nat Methods. 2022 Sep;19(9):1017-1019
pubmed: 35970936
Cancer. 2008 Jul 15;113(2):293-301
pubmed: 18457330
Ann Oncol. 2018 Jul 1;29(7):1575-1581
pubmed: 29688262
Nat Genet. 2017 May;49(5):659-665
pubmed: 28369038
Nature. 2019 Jul;571(7764):211-218
pubmed: 31207603
Clin Cancer Res. 2011 Jul 1;17(13):4550-7
pubmed: 21498393
Clin Cancer Res. 2020 Aug 15;26(16):4289-4301
pubmed: 32303540
N Engl J Med. 2015 Jul 2;373(1):23-34
pubmed: 26027431
Nat Commun. 2017 Jun 21;8:15869
pubmed: 28635960
Cancer Immunol Res. 2018 Feb;6(2):222-235
pubmed: 29301752
Ann Oncol. 2019 May 1;30(5):706-720
pubmed: 30788497
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Cancer Cell. 2021 May 10;39(5):662-677.e6
pubmed: 33861994
Cancer Res. 2001 Jul 1;61(13):5132-6
pubmed: 11431351
Clin Cancer Res. 2013 Sep 1;19(17):4792-800
pubmed: 23690483
Clin Cancer Res. 2017 Aug 1;23(15):4416-4428
pubmed: 28213366
J Immunother Cancer. 2019 May 28;7(1):139
pubmed: 31138299
Oncoimmunology. 2022 Jan 4;11(1):1993042
pubmed: 35003893
Science. 2015 Apr 3;348(6230):62-8
pubmed: 25838374
PLoS Comput Biol. 2021 Mar 25;17(3):e1008814
pubmed: 33764977
Lancet Oncol. 2017 Jun;18(6):792-802
pubmed: 28395880
Virchows Arch. 2019 Apr;474(4):449-461
pubmed: 30470934
Eur Urol. 2019 Aug;76(2):151-156
pubmed: 31151678
J Urol. 2002 Dec;168(6):2395-400
pubmed: 12441925
Cancers (Basel). 2020 Nov 12;12(11):
pubmed: 33198174
Front Oncol. 2019 Sep 04;9:859
pubmed: 31552183